Verrica Pharmaceuticals Inc. 8-K

What Happened

• On March 11, 2026, Verrica Pharmaceuticals, Inc. (VRCA) announced and furnished a press release reporting its financial results for the quarter and the year ended December 31, 2025. The announcement was filed on Form 8‑K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Press release announcing quarterly and full‑year 2025 results furnished as Exhibit 99.1 to the Form 8‑K (filed March 11, 2026).
• Reporting period covered: quarter and year ended December 31, 2025.
• Form 8‑K also includes Exhibit 104 — Cover Page Interactive Data File (inline XBRL).
• The Item 2.02 filing furnishes the company’s results; no additional operational items or executive changes were reported in this 8‑K.

Why It Matters

• This filing makes Verrica’s reported earnings and other financial metrics for Q4 and full‑year 2025 publicly available; those figures (revenue, net income/loss, cash position, and any commentary) are in the linked press release and XBRL.
• Investors should review the press release and the inline XBRL data to see the specific earnings and financial condition details, which can influence valuation and trading decisions.
• The 8‑K itself is a disclosure of results rather than a regulatory filing that changes corporate structure or leadership.